Molecular Profiling of Colorectal Cancer

Molecular Profiling of Colorectal Cancer: A Translational Research Study With a Next Generation Sequencing Panel.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04863768

Enrollment

300

Registered

2021-04-28

Start date

2006-01-01

Completion date

2022-09-30

Last updated

2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Adenocarcinoma, Colon Cancer, Colorectal Cancer

Keywords

Colon, Translational research, Gene panel

Brief summary

In this translational research study, Formalin-Fixed-Paraffin-Embedded (FFPE) tumor tissue blocks from patients with early-stage (II-III) colorectal cancer will be assessed for a comprehensive cancer gene panel from NIPD Genetics (https://www.nipd.com/) targeting regions in 37 clinically relevant cancer genes. The colorectal cancer panel includes an extended list of clinically relevant genes, designed to target clinically actionable and clinically significant mutations that will provide physicians with genetic information regarding a) prediction of the patient's response to targeted therapy, b) prognosis, that is, prediction of clinical outcome, c) diagnosis and molecular classification of colorectal cancer.

Interventions

DIAGNOSTIC_TESTGene panel

comprehensive cancer gene panel targeting regions in 37 clinically relevant cancer genes in FFPE tumor tissue blocks

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Surgically resected early-stage (II-III) colorectal cancer * Availability of biological material

Exclusion criteria

* Metastatic disease (stage IV) at initial diagnosis

Design outcomes

Primary

Measure	Time frame	Description
association between gene mutational status and overall survival	24 months	the time from diagnosis to the date of death (from any cause). Alive patients and patients lost to follow-up will be censored at the date of last follow-up
association between gene mutational status and disease-free survival	24 months	the time from colorectal cancer diagnosis to the first date of documented disease progression, death or last contact, whichever occurs first

Secondary

Measure	Time frame	Description
Descriptives	24 months	Association of any gene mutation tumor pathological stages.

Countries

Greece

Contacts

Primary ContactGeorge Papaxoinis

georgexoinis@gmail.com+302106409000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026